Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PDS BiotechnologyPDSB -5.49%30 3-Year EBITDA Growth Rate is 22.90% as of Jun. 2026, which is 88% above its 10-year median of 12.20. GuruFocus rates PDSB with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 1,127 Biotechnology companies, PDS Biotechnology ranks better than 59.98% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 22.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 3.70% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 38.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of PDS Biotechnology was 70.20% per year. The lowest was -68.80% per year. And the median was 12.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
PDS Biotechnology 3-Year EBITDA Growth Rate Related Terms
PDSB vs KPRX, ASBP, SNTI: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, PDS Biotechnology's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PDS Biotechnology 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PDS Biotechnology's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where PDS Biotechnology's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 22.90% mean?
PDS Biotechnology (PDSB) has a 3-Year EBITDA Growth Rate of 22.90% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PDS Biotechnology and its competitors. This is 88% above median its historical median of 12.20. According to the industry distribution chart, PDS Biotechnology ranks #451 out of 1127 companies in the Biotechnology industry, placing it in the top 40%.
Is PDS Biotechnology's 3-Year EBITDA Growth Rate too high?
PDS Biotechnology's current 3-Year EBITDA Growth Rate of 22.90% is 88% above median its 10-year median of 12.20. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.60. PDS Biotechnology's value of 22.90% is 56.8% above this industry median. Based on the distribution chart, PDS Biotechnology ranks #451 out of 1127 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PDS Biotechnology has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does PDS Biotechnology's 3-Year EBITDA Growth Rate compare to KPRX and ASBP?
According to the Biotechnology industry distribution chart, PDS Biotechnology ranks #451 out of 1127 companies for 3-Year EBITDA Growth Rate. This puts PDS Biotechnology in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.60. PDS Biotechnology's value of 22.90% is 56.8% above this benchmark. While the company's 10-year median is 12.20 vs. the industry median of 14.60, PDS Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.60, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PDS Biotechnology's current 3-Year EBITDA Growth Rate of 22.90% is 56.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for PDS Biotechnology and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PDS Biotechnology's current 3-Year EBITDA Growth Rate is 22.90%, which is 88% above median its own 10-year median of 12.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PDS Biotechnology stock overvalued right now?
PDS Biotechnology (PDSB) has a current 3-Year EBITDA Growth Rate of 22.90%. The current 3-Year EBITDA Growth Rate is 22.90%, which is 88% above median its 10-year median of 12.20 and 56.8% above the Biotechnology industry median of 14.60. PDS Biotechnology's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For PDS Biotechnology (PDSB), the current 3-Year EBITDA Growth Rate is 22.90% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.
30GF Score
Get the complete analysis for PDSB
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PDSB has been successfully added to your 
